A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)

NCT07229625 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

604

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Biliary Tract Cancer

Interventions

DRUG: SHR-8068 Injection
DRUG: Adebrelimab Injection
DRUG: Gemcitabine Hydrochloride for Injection
DRUG: Cisplatin Injection
DRUG: Durvalumab Injection

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.